Showing 331-340 of 1600 results for "".
- Proof of Concept: Oral Orismilast Reduces Pain, Improves Q of L in HShttps://practicaldermatology.com/news/proof-of-concept-oral-orismilast-reduces-pain-improves-q-of-l-in-hs/2461799/Oral orismilast is showing promise in adult with hidradenitis suppurativa (HS), according to positive topline results from the OSIRIS investigator-initiated proof-of-concept study. UNION therapeutics’ Orismilast is a high potency, next-generation PDE4
- Beyond BSA: IPC, NPF Call Attention to Psoriasis Lesion Location on Q of Lhttps://practicaldermatology.com/news/beyond-bsa-ipc-npf-call-attention-to-psoriasis-lesion-location-on-q-of-l/2462007/The International Psoriasis Council (IPC) is partnering with the National Psoriasis Foundation (NPF) to call attention to the influence of psoriasis lesion locations on patients’ quality of life. The joint effort presents a study that delves into how psoriasis in specific areas
- Aerolase Appoints Industry Vet Didier Leclercq to Leadership Teamhttps://practicaldermatology.com/news/aerolase-appoints-industry-vet-didier-leclercq-to-leadership-team/2460448/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med once it was acquired by G
- Dupixent Significantly Improves Severe AD in Childrenhttps://practicaldermatology.com/news/dupixent-significantly-improves-severe-ad-in-children/2460338/Dupixent showed significant improvement in severe atopic dermatitis (AD) for children aged 6 to 11 Years, according to a Phase 3 study. In the trial, Dupixent combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related q
- Galderma Rolls Out New Consumer-Facing Rewards App, Plus Morehttps://practicaldermatology.com/news/galderma-rolls-out-new-consumer-facing-rewards-app-plus-more-1/2460296/Galderma is enhancing its aesthetic portfolio with digital enhancements to Aspire Galderma Rewards, an expansion of its U.S. salesforce plus a collaboration with ZO Skin Health. "We want to enable every customer and partner to build experiences on our leading platforms,&q
- Education Credits Available: ABCs of Nitric Oxide in the Skinhttps://practicaldermatology.com/news/education-credits-available-abcs-of-nitric-oxide-in-the-skin/2458239/A free, online educational program intended to provide participants increased knowledge regarding the role of NO in maintaining a variety of physiologic processes has been launched. The program is directed by James Q. Del Rosso, DO. The program is also intended to address the correlation of
- Alma Lasers to Present New Technologies at AAD Meetinghttps://practicaldermatology.com/news/20130227-alma_lasers_to_present_new_technologies_at_aad_meeting/2459604/Alma Lasers unveiled its two latest technologies, the vShape focused radiofrequency (RF) workstation and the ClearLift. The RF workstation addresses tailored anti-aging treatments for the face, body, and cellulite. The ClearLift is Q-switched technology penetrates deep beneath the skin and decreases
- Biofrontera Announces Restructuring of Supply Agreement, Reduces Ameluz Transfer Pricinghttps://practicaldermatology.com/news/biofrontera-inc-announces-private-placement-of-up-to-160-million-priced-at-market-per-nasdaq-rules/2462246/Biofrontera has announced a restructuring of agreements with its former parent company, Biofrontera AG, aimed at enhancing long-term profitability. As a result, the transfer price of its leading product, Ameluz, indicated for the treatment of actinic keratosis, will be slashed from 50% to 25% for
- Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Updatehttps://practicaldermatology.com/news/20140623-verisante_technology_inc_announces_2014_first_quarter_results_and_provides_operational_update/2459195/Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has released its financial results for the first quarter ended March 31, 2014 .
- JAK Inhibitors' Applications Continue to Expandhttps://practicaldermatology.com/news/JAK-Inhibitors-Applications-Continue-Expand/2471523/While JAK inhibitors have become widely popular for several common skin diseases, their potential for other indications remains vast, and Ruth Ann Vleugels, MD, MPA, MPH, FAAD, highlighted some of these in “JAK Inhibitors for Lupus, Dermatomyositis, and SAVI” at the 2025 American Academy of Derma